PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is researched primarily for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant. It belongs to the Ion channel inhibitor peptide category of compounds.
What Is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability.
Demonstrates antidepressant onset in 4 days versus 4-6 weeks for conventional medications — if human efficacy confirms, this would be the fastest-acting peptide antidepressant. It has attracted significant research interest for its potential effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
How Does PE-22-28 Produce These Benefits?
Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine neurotransmission, producing rapid antidepressant effects within 4 days by stimulating hippocampal neurogenesis.
This multi-pathway activity is why PE-22-28 shows potential across several different applications rather than being limited to a single use case.
Can PE-22-28 Help With Rapid Antidepressant Effects (4 Days Vs 4-6 Weeks For Ssris)?
Research suggests PE-22-28 may support rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs) through its ion channel inhibitor peptide activity. Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
Protocols targeting rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs) typically use 100-500 mcg daily administered once daily for 4-8 weeks.
Can PE-22-28 Help With Hippocampal Neurogenesis?
Research suggests PE-22-28 may support hippocampal neurogenesis through its ion channel inhibitor peptide activity. Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
Protocols targeting hippocampal neurogenesis typically use 100-500 mcg daily administered once daily for 4-8 weeks.
Can PE-22-28 Help With Enhanced Synaptogenesis?
Research suggests PE-22-28 may support enhanced synaptogenesis through its ion channel inhibitor peptide activity. Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
Protocols targeting enhanced synaptogenesis typically use 100-500 mcg daily administered once daily for 4-8 weeks.
Can Stacking Enhance PE-22-28 Benefits?
Could theoretically pair with SSRIs for enhanced antidepressant effects through complementary serotonergic mechanisms.
See our PE-22-28 stacking guide for detailed combination protocols.
What Is the Bottom Line on PE-22-28 Benefits?
PE-22-28 is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis. The evidence base includes: Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
PE-22-28 is not fda-approved. investigational research peptide only. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.